{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T20:02:56Z","timestamp":1790280176760,"version":"4.1.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,12,1]],"date-time":"2026-12-01T00:00:00Z","timestamp":1796083200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:00:00Z","timestamp":1790121600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100018806","name":"Department of Science and Technology of Hubei Province","doi-asserted-by":"publisher","award":["CXPJJH125004-063"],"award-info":[{"award-number":["CXPJJH125004-063"]}],"id":[{"id":"10.13039\/501100018806","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003819","name":"Hubei Province Natural Science Foundation","doi-asserted-by":"publisher","award":["2024AFB034"],"award-info":[{"award-number":["2024AFB034"]}],"id":[{"id":"10.13039\/501100003819","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82503741"],"award-info":[{"award-number":["82503741"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2026,12]]},"DOI":"10.1016\/j.bcp.2026.118486","type":"journal-article","created":{"date-parts":[[2026,9,18]],"date-time":"2026-09-18T15:19:30Z","timestamp":1789744770000},"page":"118486","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P2","title":["AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer"],"prefix":"10.1016","volume":"254","author":[{"given":"Wenlong","family":"Wan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziqi","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianping","family":"Miao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"2","key":"10.1016\/j.bcp.2026.118486_b0005","first-page":"111","article-title":"Cancer statistics for African American and Black people, 2025","volume":"75","author":"Saka","year":"2025","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2026.118486_b0010","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.canlet.2021.03.012","article-title":"CDK7 inhibition by THZ1 suppresses cancer stemness in both chemona\u00efve and chemoresistant urothelial carcinoma via the hedgehog signaling pathway","volume":"507","author":"Chow","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.bcp.2026.118486_b0015","doi-asserted-by":"crossref","first-page":"1791","DOI":"10.2147\/OTT.S186271","article-title":"A meta-analysis of the efficacy and safety of PD-1\/PD-L1 immune checkpoint inhibitors as treatments for metastatic bladder cancer","volume":"12","author":"Fan","year":"2019","journal-title":"OncoTargets Therapy"},{"key":"10.1016\/j.bcp.2026.118486_b0020","article-title":"Safety and activity of programmed cell death 1 versus programmed cell death ligand 1 inhibitors for platinum-resistant urothelial cancer: a meta-analysis of published clinical trials","volume":"11","author":"Li","year":"2021","journal-title":"Front. Oncol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118486_b0025","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1038\/s41401-022-01047-6","article-title":"AXL antibody and AXL-ADC mediate antitumor efficacy via targeting AXL in tumor-intrinsic epithelial-mesenchymal transition and tumor-associated M2-like macrophage","volume":"44","author":"Pei","year":"2023","journal-title":"Acta Pharmacol. Sin."},{"issue":"5","key":"10.1016\/j.bcp.2026.118486_b0030","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1007\/s10120-020-01066-4","article-title":"Inhibiting the GAS6\/AXL axis suppresses tumor progression by blocking the interaction between cancer-associated fibroblasts and cancer cells in gastric carcinoma","volume":"23","author":"Bae","year":"2020","journal-title":"Gastric Cancer"},{"issue":"2","key":"10.1016\/j.bcp.2026.118486_b0035","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1159\/000520501","article-title":"AXL and MET in hepatocellular carcinoma: a systematic literature review","volume":"11","author":"Hsu","year":"2022","journal-title":"Liver Cancer."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0040","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1038\/s41598-022-09078-z","article-title":"AXL inhibition improves BRAF-targeted treatment in melanoma","volume":"12","author":"Nyakas","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.bcp.2026.118486_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2023.1139998","article-title":"Identifying key genes related to inflammasome in severe COVID-19 patients based on a joint model with random forest and artificial neural network","volume":"13","author":"Ou","year":"2023","journal-title":"Front. Cell. Infect. Microbiol."},{"key":"10.1016\/j.bcp.2026.118486_b0050","doi-asserted-by":"crossref","first-page":"718","DOI":"10.3389\/fimmu.2020.00718","article-title":"The Emerging Role of the IL-17B\/IL-17RB Pathway in Cancer","volume":"11","author":"Bastid","year":"2020","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0055","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1186\/s40425-019-0757-z","article-title":"IL-17 inhibits CXCL9\/10-mediated recruitment of CD8(+) cytotoxic T cells and regulatory T cells to colorectal tumors","volume":"7","author":"Chen","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118486_b0060","doi-asserted-by":"crossref","unstructured":"Ramirez-Carrozzi V, Ota N, Sambandam A, Wong K, Hackney J, Martinez-Martin N, et al. Cutting Edge: IL-17B Uses IL-17RA and IL-17RB to Induce Type 2 Inflammation from Human Lymphocytes. Journal of immunology (Baltimore, Md : 1950). 2019;202(7):1935-41.","DOI":"10.4049\/jimmunol.1800696"},{"issue":"8","key":"10.1016\/j.bcp.2026.118486_b0065","doi-asserted-by":"crossref","first-page":"1837","DOI":"10.1084\/jem.20070406","article-title":"IL-25 augments type 2 immune responses by enhancing the expansion and functions of TSLP-DC-activated Th2 memory cells","volume":"204","author":"Wang","year":"2007","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118486_b0070","article-title":"The central role of IL-17 in cancer stemness and immune evasion: a novel axis for overcoming immune checkpoint inhibitor resistance","volume":"217","author":"Wang","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"4","key":"10.1016\/j.bcp.2026.118486_b0075","article-title":"Targeting interleukin-17 enhances tumor response to immune checkpoint inhibitors in colorectal cancer","volume":"1877","author":"Li","year":"2022","journal-title":"Biochim. Biophys. Acta"},{"issue":"12","key":"10.1016\/j.bcp.2026.118486_b0080","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1158\/1078-0432.CCR-18-4085","article-title":"The immune subtypes and landscape of squamous cell carcinoma","volume":"25","author":"Li","year":"2019","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.bcp.2026.118486_b0085","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12071788","article-title":"Characterization of glycolysis-associated molecules in the tumor microenvironment revealed by pan-cancer tissues and lung cancer single cell data","volume":"12","author":"Wei","year":"2020","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0090","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12943-024-02210-9","article-title":"AXL: shapers of tumor progression and immunosuppressive microenvironments","volume":"24","author":"Liu","year":"2025","journal-title":"Mol. Cancer"},{"issue":"24","key":"10.1016\/j.bcp.2026.118486_b0095","doi-asserted-by":"crossref","DOI":"10.3390\/cells11244077","article-title":"A combined risk score model to assess prognostic value in patients with soft tissue sarcomas","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.bcp.2026.118486_b0100","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2025.1601420","article-title":"Axl inhibitor-mediated reprogramming of the myeloid compartment of the in vitro tumor microenvironment is influenced by prior targeted therapy treatment","volume":"16","author":"Datta","year":"2025","journal-title":"Front. Immunol."},{"issue":"6","key":"10.1016\/j.bcp.2026.118486_b0105","doi-asserted-by":"crossref","DOI":"10.3390\/cancers17060994","article-title":"Axl regulation of NK cell activity creates an immunosuppressive tumor immune microenvironment in head and neck cancer","volume":"17","author":"Kostecki","year":"2025","journal-title":"Cancers"},{"issue":"7","key":"10.1016\/j.bcp.2026.118486_b0110","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1158\/0008-5472.CAN-20-0434","article-title":"Cooperative targeting of immunotherapy-resistant melanoma and lung cancer by an AXL-targeting antibody-drug conjugate and immune checkpoint blockade","volume":"81","author":"Boshuizen","year":"2021","journal-title":"Cancer Res."},{"issue":"6","key":"10.1016\/j.bcp.2026.118486_b0115","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002603","article-title":"Type 17 immunity promotes the exhaustion of CD8(+) T cells in cancer","volume":"9","author":"Kim","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0120","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001895","article-title":"Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer","volume":"9","author":"Liu","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.bcp.2026.118486_b0125","article-title":"Incorporation of SKI-G-801, a Novel AXL Inhibitor, with Anti-PD-1 Plus Chemotherapy Improves Anti-Tumor activity and Survival by Enhancing T Cell Immunity","volume":"12","author":"Lee","year":"2022","journal-title":"Front. Oncol."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0130","doi-asserted-by":"crossref","first-page":"e1364","DOI":"10.1002\/cti2.1364","article-title":"SKI-G-801, an AXL kinase inhibitor, blocks metastasis through inducing anti-tumor immune responses and potentiates anti-PD-1 therapy in mouse cancer models","volume":"11","author":"Synn","year":"2022","journal-title":"Clin. Transl. Immunol."},{"issue":"3","key":"10.1016\/j.bcp.2026.118486_b0135","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1158\/0008-5472.CAN-20-2066","article-title":"Axl and mertk receptors cooperate to promote breast cancer progression by combined oncogenic signaling and evasion of host antitumor immunity","volume":"81","author":"Davra","year":"2021","journal-title":"Cancer Res."},{"issue":"2","key":"10.1016\/j.bcp.2026.118486_b0140","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/s41419-024-06493-0","article-title":"Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer","volume":"15","author":"Xie","year":"2024","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.bcp.2026.118486_b0145","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116475","article-title":"Recent discovery and development of AXL inhibitors as antitumor agents","volume":"272","author":"Liu","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"12","key":"10.1016\/j.bcp.2026.118486_b0150","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20190354","article-title":"Interleukin-17-induced neutrophil extracellular traps mediate resistance to checkpoint blockade in pancreatic cancer","volume":"217","author":"Zhang","year":"2020","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.bcp.2026.118486_b0155","article-title":"AXL kinase inhibition promotes cytosolic DNA sensor cGAS activity and sensitizes poorly immunogenic tumors to chemo-immunotherapy","author":"Dhakal","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.bcp.2026.118486_b0160","doi-asserted-by":"crossref","unstructured":"Goyette MA, Elkholi IE, Apcher C, Kuasne H, Rothlin CV, Muller WJ, et al. Targeting Axl favors an antitumorigenic microenvironment that enhances immunotherapy responses by decreasing Hif-1\u03b1 levels. Proceedings of the National Academy of Sciences of the United States of America. 2021;118(29).","DOI":"10.1073\/pnas.2023868118"},{"issue":"6","key":"10.1016\/j.bcp.2026.118486_b0165","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20210693","article-title":"IL-17-induced HIF1\u03b1 drives resistance to anti-PD-L1 via fibroblast-mediated immune exclusion","volume":"219","author":"Chen","year":"2022","journal-title":"J. Exp. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0170","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1186\/s12967-023-04365-3","article-title":"IL-17A promotes tumorigenesis and upregulates PD-L1 expression in non-small cell lung cancer","volume":"21","author":"Liao","year":"2023","journal-title":"J. Transl. Med."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0175","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1038\/s41368-023-00267-8","article-title":"Spatial transcriptomics reveals that metabolic characteristics define the tumor immunosuppression microenvironment via iCAF transformation in oral squamous cell carcinoma","volume":"16","author":"Liu","year":"2024","journal-title":"Int. J. Oral Sci."},{"issue":"2","key":"10.1016\/j.bcp.2026.118486_b0180","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1158\/2767-9764.CRC-23-0192","article-title":"Lingual denervation improves the efficacy of Anti-PD-1 immunotherapy in oral squamous cell carcinomas by downregulating TGF\u03b2 signaling","volume":"4","author":"Tao","year":"2024","journal-title":"Cancer Res. Commun."},{"issue":"1","key":"10.1016\/j.bcp.2026.118486_b0185","doi-asserted-by":"crossref","first-page":"2846","DOI":"10.1038\/s41467-025-58179-6","article-title":"Bemcentinib as monotherapy and in combination with low-dose cytarabine in acute myeloid leukemia patients unfit for intensive chemotherapy: a phase 1b\/2a trial","volume":"16","author":"Loges","year":"2025","journal-title":"Nat. Commun."},{"key":"10.1016\/j.bcp.2026.118486_b0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.lungcan.2023.107291","article-title":"Phase 1 trial of bemcentinib (BGB324), a first-in-class, selective AXL inhibitor, with docetaxel in patients with previously treated advanced non-small cell lung cancer","volume":"182","author":"Bhalla","year":"2023","journal-title":"Lung Cancer"},{"issue":"25","key":"10.1016\/j.bcp.2026.118486_b0195","article-title":"S100A5 attenuates efficiency of anti-PD-L1\/PD-1 immunotherapy by inhibiting CD8(+) T cell-mediated anti-cancer immunity in bladder carcinoma","volume":"10","author":"Li","year":"2023","journal-title":"Adv Sci (weinh)"}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008282?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295226008282?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T19:39:17Z","timestamp":1790278757000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295226008282"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,12]]},"references-count":39,"alternative-id":["S0006295226008282"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118486","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2026,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"AXL drives immunotherapy resistance by modulating IL-17 in bladder cancer","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2026.118486","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"118486"}}